Leukemia Research
Volume 33, Issue 9 , Pages 1189-1193 , September 2009

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

  • Sebastian Balleisen

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany
    • Department of Human Genetics, Heinrich-Heine University, 40225 Düsseldorf, Germany
    • ,
  • Andrea Kuendgen

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany
    • Department of Human Genetics, Heinrich-Heine University, 40225 Düsseldorf, Germany
    • Corresponding Author InformationCorresponding author at: Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, Düsseldorf, Germany. Tel.: +49 211 8117720; fax: +49 211 8118853.
    • ,
  • Barbara Hildebrandt

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany
    • Department of Human Genetics, Heinrich-Heine University, 40225 Düsseldorf, Germany
    • ,
  • Rainer Haas

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany
    • Department of Human Genetics, Heinrich-Heine University, 40225 Düsseldorf, Germany
    • ,
  • Ulrich Germing

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany
    • Department of Human Genetics, Heinrich-Heine University, 40225 Düsseldorf, Germany

Received 30 August 2008 ,Revised 1 March 2009 ,Accepted 3 March 2009.

References 

  1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336
  2. Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2002;8:435–443
  3. Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223–2231
  4. Haferlach T, Kern W, Schoch C, Schnittger S, Sauerland MC, Heinecke A, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica. 2004;89:408–418
  5. Knipp S, Hildebrandt B, Giagounidis AAN, Kobbe G, Haas R, Aul C, et al. Intensive chemotherapy is not recommended for patients with AML or high-risk AML aged over 60 years with complex karyotype anomalies. Blood. 2004;104:24a
  6. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17–31
  7. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521–1528
  8. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120–125
  9. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology-Group-Study. Blood. 2000;96:4075–4083
  10. Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia. 2004;18:293–302
  11. Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol. 2004;22:2410–2418
  12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR. Proposals for the classification of the myelodysplastic syndromes.. Br J Haematol. 1982;51:189–199
  13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976;33:451–458
  14. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid. J Clin Oncol. 2003;21:4642–4649
  15. In:  Mitelman F editors. ISCN: an international system for human cytogenetics nomenclature. Switzerland, Karger: Basel; 1995;
  16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333
  17. Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica. 2007;92(3):315–322
  18. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia. 2007;21(6):1177–1182

PII: S0145-2126(09)00111-8

doi: 10.1016/j.leukres.2009.03.004

Leukemia Research
Volume 33, Issue 9 , Pages 1189-1193 , September 2009

Article Tools

* Image Usage & Resolution